Welcome to LookChem.com Sign In|Join Free
  • or
4-KETO 13-CIS-RETINOIC ACID METHYL ESTER is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

71748-57-7

Post Buying Request

71748-57-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

71748-57-7 Usage

Chemical Properties

Yellow Solid

Check Digit Verification of cas no

The CAS Registry Mumber 71748-57-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,7,4 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 71748-57:
(7*7)+(6*1)+(5*7)+(4*4)+(3*8)+(2*5)+(1*7)=147
147 % 10 = 7
So 71748-57-7 is a valid CAS Registry Number.

71748-57-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoate

1.2 Other means of identification

Product number -
Other names 4-Keto 13-cis-Retinoic Acid Methyl Ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:71748-57-7 SDS

71748-57-7Relevant academic research and scientific papers

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-OXOISOTRETINOIN

-

, (2022/02/28)

The present invention relates to an improved process for the preparation of 4-Oxoisotretinoin and purification process of 4-Oxoisotretinoin (I) and crystalline 5 form of 4-Oxoisotretinoin (I).

Preparation method of olefine acid impurity

-

, (2021/01/11)

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of an olefine acid impurity. The impurity is (13E) -3, 7-dimethyl -9 -[(3RS) -3-methoxy -2, 6, 6-trimethyl cyclohexenyl] -2, 4, 6, 8-azela

13-CIS-RAMBA RETINAMIDES THAT DEGRADE MNKS FOR TREATING CANCER

-

Page/Page column 53, (2016/06/20)

The synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling are discussed. In both breast and prostate cancer cell lines, these compounds induc

Novel C-4 heteroaryl 13- cis -retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice

Mbatia, Hannah W.,Ramalingam, Senthilmurugan,Ramamurthy, Vidya P.,Martin, Marlena S.,Kwegyir-Afful, Andrew K.,Njar, Vincent C. O.

, p. 1900 - 1914 (2015/04/27)

The synthesis and in vitro and in vivo antibreast and antiprostate cancers activities of novel C-4 heteroaryl 13-cis-retinamides that modulate Mnk-eIF4E and AR signaling are discussed. Modifications of the C-4 heteroaryl substituents reveal that the 1H-imidazole is essential for high anticancer activity. The most potent compounds against a variety of human breast and prostate cancer (BC/PC) cell lines were compounds 16 (VNHM-1-66), 20 (VNHM-1-81), and 22 (VNHM-1-73). In these cell lines, the compounds induce Mnk1/2 degradation to substantially suppress eIF4E phosphorylation. In PC cells, the compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to inhibit AR transcriptional activity. More importantly, VNHM-1-81 has strong in vivo antibreast and antiprostate cancer activities, while VNHM-1-73 exhibited strong in vivo antibreast cancer activity, with no apparent host toxicity. Clearly, these lead compounds are strong candidates for development for the treatments of human breast and prostate cancers.

Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice

Patel, Jyoti B.,Huynh, Carlic K.,Handratta, Venkatesh D.,Gediya, Lalji K.,Brodie, Angela M. H.,Goloubeva, Olga G.,Clement, Omoshile O.,Nanne, Ivo P.,Soprano, Dianne Robert,Njar, Vincent C. O.

, p. 6716 - 6729 (2007/10/03)

Novel retinoic acid metabolism blocking agents (RAMBAs) have been synthesized and characterized. The synthetic features include introduction of nucleophilic ligands at C-4 of all-trans-retinoic acid (ATRA) and 13-cis-retinoic acid, and modification of ter

A convenient synthesis of retinal derivatives with modified trimethylcyclohexene ring

Mironova,Leont'eva,Shevyakov,Alexeeva,Shvets,Demina,Krasnokutskaya,Finkel'shtein,Khodonov

, p. 487 - 493 (2007/10/03)

A method of simultaneous one-stage synthesis of three retinal derivatives (5,6-dioxo-5,6-seco-, 5,6-dihydro-5,6-epoxy-, and 4-oxoretinal) was proposed, with the yield of the first derivative being ~50%. These compounds are useful tools for studying the an

Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids

Njar, Vincent C.O.,Nnane, Ivo P.,Brodie, Angela M.H.

, p. 1905 - 1908 (2007/10/03)

Novel (±)-4-azolyl retinoic acid analogues 4, 5, 7 and 8 have been designed and synthesized and have been shown to be powerful inhibitors of hamster microsomal all-trans-retinoic acid 4-hydroxylase enzyme(s). (±)-4-(1H-Imidazol-1-yl)retinoic acid (4) is t

Specific oxidation of retinoic acid to 4-oxo-retinoic acid in diluted acid solutions

Tanaka,Kagechika,Shudo

, p. 356 - 358 (2007/10/02)

Treatment of retinoic acid (1a) or its methyl ester (2a) with hydrochloric acid in methanol gave methyl 4-oxo-retinoates (4a - c). Similar oxidation proceeded when 2a was treated with trifluoromethanesulfonic acid in the presence of lithium chloride in methanol.

Cancer Chemopreventive 3-Substituted-4-oxoretinoic Acids

Shealy, Y. Fulmer,Hosmer, Carla A.,Riordan, James M.,Wille, John W.,Rogers, Tina S.,Hill, Donald L.

, p. 3051 - 3056 (2007/10/02)

The introduction of substituents at position 3 of methyl 4-oxoretinoate can be effected in good yields by alkylating the lithium dienolate.A second substituent can be introduced also, but the resulting 3,3-disubstituted-4-oxoretinoates were isolated in lo

Modification of the intact retinoid structure in the cyclohexenyl region: Alkylation of methyl 4-oxoretinoate

Shealy,Hosmer,Riordan

, p. 1095 - 1098 (2007/10/02)

Alkylation of methyl 4-oxoretinoate under kinetic-control conditions gives predominantly 3-alkyl-4-oxoretinoates. 3,3-Disubstituted 4-oxoretinoates are obtained similarly from the 3-monosubstituted derivatives, although introduction of the second substituent is more difficult. Evidence has been obtained for a much slower rate of alkylation α to the ester group.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 71748-57-7